Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 12/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.34 |
| ▸ | KDM4A | O75164 | 2/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.34 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.34 |
| ▸ | TET3 | O43151 | 1/20 | 0.34 |
| ▸ | GABRP | O00591 | 2/20 | 0.33 |
| ▸ | GABRD | O14764 | 2/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.33 |
| ▸ | GABRE | P78334 | 2/20 | 0.33 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18516705 | 0.92 | FOLH1 (0.40) | FOLH1CYP1A2TET2KDM4AKDM4C | |
| SCHEMBL28897504 | 0.84 | FOLH1 (0.51) | FOLH1CYP1A2TET2KDM4AKDM4C | |
| SCHEMBL19606545 | 0.81 | FOLH1 (0.44) | FOLH1CYP1A2TET2KDM4AKDM4C | |
| SCHEMBL7600702 | 0.78 | FOLH1 (0.44) | FOLH1CYP1A2TET2KDM4AKDM4C | |
| SCHEMBL465915 | 0.73 | TET2 (0.56) | FOLH1CYP1A2TET2KDM4AKDM4C | |
| SCHEMBL13849512 | 0.73 | TSHR (0.50) | SLC1A3SLC1A2SLC1A1ALOX15 | |
| SCHEMBL255602 | 0.73 | TSHR (0.50) | SLC1A3SLC1A2SLC1A1ALOX15 | |
| SCHEMBL7092944 | 0.73 | TSHR (0.50) | SLC1A3SLC1A2SLC1A1ALOX15 | |
| SCHEMBL6263449 | 0.73 | FOLH1 (0.45) | FOLH1CYP1A2TET2KDM4AKDM4C | |
| SCHEMBL1442538 | 0.73 | TSHR (0.50) | SLC1A3SLC1A2SLC1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200281501-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC | 2020-09-10 | — | — | US | disclosed |
| US-20170325708-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | AGIOS PHARMACEUTICALS, INC. (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170044620-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC | 2017-02-16 | — | — | US | disclosed |
| US-9434979-B2 | Methods and compositions for cell-proliferation-related disorders | SERVIER PHARMACEUTICALS LLC | 2016-09-06 | — | — | US | disclosed |
| US-20150240286-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | AGIOS PHARMACEUTICALS, INC (US) | 2015-08-27 | — | — | US | disclosed |
| US-20130288284-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC | 2013-10-31 | — | — | US | disclosed |
| US-20130183281-A1 | METHODS AND COMPOSITONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC | 2013-07-18 | — | — | US | disclosed |
| US-20120121515-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170325708-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | MKI67, BRCA1, CLN6 | FOLH1 1283/4885CYP1A2 4813/4885TET2 1365/4885 |
| US-20120121515-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | MKI67, BRCA1, CLN6 | FOLH1 1283/4885CYP1A2 4813/4885TET2 1365/4885 |
| US-20130183281-A1 | METHODS AND COMPOSITONS FOR CELL-PROLIFERATION-RELATED DISORDERS | IDH2, IDH1, MKI67 | FOLH1 601/4885CYP1A2 3900/4885TET2 27/4885 |
| US-20200281501-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | MKI67, BRCA1, CLN6 | FOLH1 1283/4885CYP1A2 4813/4885TET2 1365/4885 |
| US-20170044620-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | IDH2, IDH1, IDH3B | FOLH1 1027/4885CYP1A2 4175/4885TET2 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.